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Childrena b s t r a c t
Data on epidemiology of severe infectious complications, ie, bacteremia or invasive fungal disease (IFD), in
children with acute graft-versus-host disease (aGVHD) after allogeneic hemopoietic stem cell transplantation
(HSCT) are scarce. In a retrospective, single-center study, we analyzed the risk (hazard ratio [HR]) and the rate
(episodes/1000 patients days at risk) of bacteremias and IFD in children receiving allogeneic HSCT, according
to the type of donor (matched related [MRD] or alternative [AD]) and presence and grade of aGVHD. From
2000 to 2009, 198 children receiving 217 allogeneic HSCT developed 134 severe infectious episodes
(103 bacteremias and 31 IFD). The type of donor (AD versus MRD) was the most important risk factor for the
severe infections (P ¼ .0052). In separate multivariable analysis for bacteremia and IFD, children receiving an
AD HSCT had increased HR and rate of bacteremia compared with those receiving a MRD transplantation
(P ¼ .0171 and P ¼ .0001, respectively), whereas the HR and the rate of IFD were signiﬁcantly inﬂuenced by the
grade of aGVHD (P ¼ .0002 and P < .0001, respectively). Finally, infectious episodes occurred late after HSCT,
especially in presence of severe aGVHD, and bacteremias were 3 to 6 times more frequent than IFD. These
data may be important to design management strategies of infections in pediatric allogeneic HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bacteremia and invasive fungal diseases (IFD) represent
severe complications for patients receiving allogeneic
hemopoietic stem cell transplantation (HSCT) [1-4]. These
infections are more frequent in subjects receiving HSCT from
an alternative donor (AD) than from a matched related donor
(MRD) [1]. During a prospective survey of adverse events
occurring in patients with steroid-resistant acute graft-
versus-host disease (aGVHD), we observed that the
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previously reported [5]. The major criticism to that study was
that incidence was compared with that observed in a “gen-
eral” population of pediatric allogeneic HSCT recipients, as no
datawere available for the subgroup of childrenwith aGVHD.
The aim of the present study was to analyze the role of
aGVHD in the risk of severe infectious complications
(bacteremia and IFD) in pediatric allogeneic HSCT recipients.
PATIENTS AND METHODS
Clinical records of children or adolescents with cancer or other
hematological disorders who received allogeneic HSCT at the Hematopoietic
Stem Cell Unit of the Istituto Giannina Gaslini in Italy between January 2000
and December 2009 were reviewed for the occurrence of aGVHD and
development of bacteremia or IFD. The period at risk for developing aGVHD
or any infectious episode was deﬁned as the interval between the day of
transplantation and that of discontinuation of any immunosuppressive
treatment, which could have been due to its elective end, relapse, or death,
whichever occurred ﬁrst. If a subsequent transplantation was performed,
another treatment period was calculated using the same criteria as stated
above, starting from the date of the subsequent HSCT. Follow-up informa-
tion was censored at June 30, 2011.
For each eligible patient, data on demographics, underlying disease, date
and type of transplantation(s), development of aGVHD (date of onset and
end, maximum grade, and refractoriness to steroids), and updated follow-up
status were already available in an institutional database. In a separate
database, information (ie, etiology, localization, and date of diagnosis) had
also been prospectively collected on any infectious episode. Bacteremia and
IFD were classiﬁed as previously described [1], but for IFD, the revised
version of the European Organization for Research and Treatment of Cancer/
Mycosis Study Group criteria was adopted [6].
For the purpose of this study, the underlying disease was categorized as
malignant (including leukemias, lymphomas, hemophagocytic lymphohis-
tiocytosis, and solid tumors) and nonmalignant (including severe aplastic
anemia, Fanconi anemia, immunodeﬁciency, and inborn errors). Recipients
of transplants from an HLA-geno/phenotypically identical donor or from
a single-locusemismatched related donor were categorized as receiving a
MRD HSCT, whereas recipients of transplants from an unrelated source
(adult volunteer or cord blood) or from a related donor with more than 1
HLA mismatch were classiﬁed as receiving an AD HSCT. The source of stem
cells was categorized as bone marrow, peripheral blood stem cells, or um-
bilical cord blood. The conditioning regimen was deﬁned as myeloablative
(MA) or nonmyeloablative. According to our previous deﬁnitions [7], aGVHD
was grouped into 3 categories: (1) not evaluable, in case of primary graft
failure or rejection and in case of death before engraftment; (2) absent or
mild in case of grades 0 to I; and (3) severe in case of grades II to IV. Acute
GVHD was further deﬁned as refractory to ﬁrst-line therapy when clinical
signs (cutaneous, intestinal, or hepatic) worsened or remained stable 5 to 7
days after starting of standard methylprednisolone therapy.
All patients older than 18 years, or the parents or guardians of younger
children, had signed a consent form allowing the use of their data for clinical
research purposes. The procedures we followed were in accordance with
our institution’s ethical standards and with the declaration of Helsinki
principles.
STANDARD OF CARE
The conditioning regimen was usually MA for patients
affected by malignancy or by a congenital disease, whereas
for children affected by acquired or congenital aplastic ane-
mia, or with severe comorbidities, the conditioning regimen
was usually given at nonmyeloablative doses.
As previously described [7], GVHD prophylaxis varied
according to the type of donor and to the diagnosis (ma-
lignant versus nonmalignant disease). Patients with malig-
nant disease undergoing hemopoietic stem cell transplant
from a matched related donor received cyclosporine (2 mg/
kg/day in 2 doses) or tacrolimus (.01 mg/kg/day c.i.) alone,
whereas a short course methotrexate (10 mg/m2 at day þ1, 8
mg/m2 at day þ3,þ6,þ11) was added to the therapy of MRD
recipients with a nonmalignant disorder. Rabbit anti-
lymphocyte serum (ATG) (Thymoglobulin, Genzyme, Cam-
bridge, MA) was added to the cyclosporine/short-course
methotrexate regimen for patients receiving HSCT from anAD. The dose and timing of ATG varied from 2.5 mg/kg for 2
days to 3.75 mg/kg for 3 days, based on donor-recipient HLA
compatibility.
In case of grade > II GVHD, standard methylprednisolone
therapy at 2 mg/kg/day was started, and a second-line
therapy was considered in case of resistant aGVHD [8].
During the peri- and post-transplantation period, and until
discharge from the hospital, patients were admitted in single
rooms with air conditioning and high-efﬁciency particulate
air ﬁlters. Oral amoxicillin-clavulanate or intravenous
ampicillin-sulbactam were administered as antibacterial
prophylaxis during the pre-engraftment period, and ﬂucon-
azole was administered as antifungal prophylaxis up to day
100 after HSCT. Secondary antifungal prophylaxis was
administered to all patients with a positive history of IFD
before HSCT. All patients received prophylaxis for Pneumo-
cystis jirovecii pneumonia starting the second week after
HSCT and until the end of immunosuppressive treatment.STATISTICAL ANALYSIS
Descriptive statistics were performed in terms of absolute
frequencies and percentages for qualitative data, and the
Pearson’s chi-square test or Fisher exact test, if appropriate,
were applied to compare proportions. Quantitative data
were described in terms of median values and interquartile
range values because of their non-normal (Gaussian)
distribution.
Analysis was performed considering the overall burden of
severe infections. Separate analyses were also performed for
bacteremia and IFD. For univariate and multivariable anal-
ysis, the counting process approach was applied to take into
account that any patient could have received more than 1
HSCT and/or developed more than 1 infection episode [9].
For these reasons, the transplantation-related risk factors
(age at HSCT, type of donor, source of stem cell, type of
conditioning regimen, and aGVHD occurrence) were
considered as time-dependent covariates.
To adjust the analysis for competing risks, relapse or
death were the competing risks. Risk factors associated with
infections were identiﬁed in univariate and multivariable
proportional subdistribution hazard regression model ac-
cording to the method of Fine and Gray [10]. All variables,
except refractory aGVHD because it was strictly associated
with severe aGVHD, were entered into the multivariable
models and then, to test the best-ﬁt model, they were
sequentially eliminated in a stepwise backward selection
procedure until all remaining variables were statistically
signiﬁcant. The subdistribution hazard ratio (HR) with the
95% conﬁdence interval (CI) was calculated using a robust
estimate of variance to incorporate the intraindividual cor-
relation, and the likelihood ratio test was calculated to
measure the effect of each predictor. Proportional hazard
assumption was tested using scaled Schoenfeld residuals
against log of time.
The rates of bacteremia and IFD were calculated as the
number of events observed divided by the duration of
follow-up (the interval between the day of transplantation
and that of discontinuation of any immunosuppressive
treatment) and expressed as episodes/1000 person-day at
risk and reported with 95% CI. The incidence rate ratio was
calculated by a Poisson regression model and the 95% CI was
estimated using a robust estimate of variance to incorporate
the intraindividual correlation. The likelihood ratio test was
calculated to measure the effect of each predictor.
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statistically signiﬁcant. All analyses were performed by using
Stata (StataCorp. Stata Statistical Software, Release 11.0 Col-
lege Station, TX).RESULTS
During the study period,198 patients underwent a total of
217 allogeneic HSCT, with 8.1% (n¼ 16) receivingmore than 1
HSCT, and their total follow-up timewas 104,117 person-days
at risk. Table 1 summarizes the demographic data and the
general characteristics of the performed transplantations.
For 20 transplantations (9.2%), aGVHD was not evaluable
because of absence of engraftment, it was absent or mildTable 1
Characteristics of Evaluable Patients Undergoing Allogeneic HSCT
Characteristic Value
Patient characteristics
No. patients 198
No. transplantations 217
Gender, n (%)
Male 120 (60.6)
Female 78 (39.4)
Underlying disease, n (%)
Nonmalignant 59 (29.8)
Malignant 139 (70.2)
Number of HSCT procedures, n (%)
1 182 (91.9)
2 13 (6.6)
3 3 (1.5)
Number of infectious episodes, n (%)
0 (none) 109 (55.0)
1 55 (27.8)
2 23 (11.6)
3 11 (5.6)
Immunosuppression days,
median (IQR)
385.5 (187-698)
Transplantation characteristics
No. of allogeneic transplantations 217
Age at HSCT, median (IQR), years 8.4 (3.4-12.1)
Type of donor, n (%)
Matched related donor 59 (27.2)
Alternative donor 158 (72.8)
Source of stem cells, n (%)
Bone marrow 167 (77.0)
Cord blood 25 (11.5)
Peripheral blood stem cells 25 (11.5)
Type of conditioning regimen, n (%)
Nonmyeloablative 54 (24.9)
Myeloablative 163 (75.1)
Grade of acute GVHD, n (%)
Absent/mild 97 (44.7)
Grade 0 55 (56.7)
Grade I 42 (43.3)
Severe 100 (46.1)
Grade II 55 (55.0)
Grade III 25 (25.0)
Grade IV 20 (20.0)
Not evaluable (not engraftment) 20 (9.2)
Refractory acute GVHD 38 (17.5)
Days to infection,
median (IQR); min-max [n]
Bacteremia 19 (6-167); 1-961 [103]
Grade 0-I 12 (5-131); 1-443 [85]
Grade II-IV 149 (107-310); 15-961 [16]
Not evaluable 7 (4-11), 4-11 [2]
Invasive fungal disease 67 (8-127); 1-487 [31]
Grade 0-I 15 (7-127); 3-250 [13]
Grade II-IV 108 (91-136); 43-487 [12]
Not evaluable 9 (7-15); 1-42 [6]
HSCT indicates hemopoietic stem cell transplantation; IQR, interquartile
range; GVHD, graft-versus-host disease.(grade 0 to I) in 44.7% of cases, and it was severe (grade II to
IV) in 100 (46.1%).
At least 1 infectious episode was diagnosed in 89
(44.9%) patients, and 34 (38.2%) experienced more than 1
episode, for a total of 134 infections: 97 single-agent bac-
teremias (72.4%), 6 mixed infection (4.5%), and 31 IFD
(23.1%). Gram-positives were isolated as a single pathogen
in 53 bacteremic episodes, whereas single-agent Gram-
negative bacteremia was diagnosed in 44. In the 6 mixed
infections, etiologies were represented only by bacteria
(6 Gram-negatives and 6 Gram-positives), and no case of
mixed bacterial-fungal infection was documented. As a
consequence, there were a total of 103 bacteremic epi-
sodes. As for IFD, isolated fungemia without deep organ
localization was diagnosed in 6 (19.4%) cases, a proven-
probable IFD with deep organ involvement in 17 (54.8%),
and possible IFD was considered in 8 (25.8%) episodes.
Table 1 also reports on time distribution since HSCT of the
infectious complications by grade of aGVHD.
Table 2 reports on analysis of risk factors associated with
the development of a severe infectious episode. Only the
type of donor was signiﬁcantly associated with HR of
infection, both in univariate (P ¼ .0022) and multivariable
(P ¼ .0052) analysis. In more detail, children receiving AD
HSCT had a 94% (univariate) and 91% (multivariable)
increased risk of infections compared with those receiving
MRD transplantation.
The risk factors associated with the development of bac-
teremias and IFD considered separately were analyzed both in
univariate and multivariable analyses. As for the risk of
bacteremia, univariate analysis showed a signiﬁcant associa-
tion of the HR only with the type of HSCT donor (P ¼ .0147),
with higher risk after AD HSCT (HR, 1.81; 95% CI, 1.31 to 2.02).
This result was conﬁrmed in the multivariable model (Table 3,
Panel A), where the type of donor resulted in the only variable
signiﬁcantly associated with the development of bacteremia.
Interestingly, the effect of the grade of aGVHD was not sta-
tistically signiﬁcant, but it is noteworthy that the HR of
bacteremia was almost 3 times lower (HR, .32) in patients not
evaluable for acute GVHD (engraftment failure or early death)
as compared with those with absent/mild disease.
Regarding the risk of IFD, univariate analysis showed a
signiﬁcant association with the grade of aGVHD (P ¼ .0002)
that resulted higher in presence of severe aGVHD (HR, 3.26;
95% CI, 1.58 to 6.71) and it was highest when aGVHD was
not evaluable (HR, 8.01; 95% CI, 3.59 to 17.88). Also, the
presence of refractory aGVHD (P ¼ .0150), with a 3.03 HR
(95% CI, 1.60 to 5.77), was associated with the risk of IFD in
univariate analysis. However, the multivariable analysis
(Table 3, Panel B) showed that the HR was signiﬁcantly
associated only with the grade of aGVHD (P ¼ .0002).
Compared with children with absent or mild aGVHD, the
risk of IFD was more than 3 times higher in children with
severe aGVHD, but it was almost 9 times higher when
GVHD was not evaluable. The association with refractory
aGVHD was no longer present in the multivariable model.
Results of all multivariable models (overall severe in-
fections, bacteremia, IFD) were conﬁrmed also in the step-
wise backward selection procedure (data not shown).
The rates of bacteremias and IFD, according to HSCT
donor type and grade of aGVHD, were also analyzed. In
univariate analysis, the type of donor was signiﬁcantly
associated with the rates of both bacteremia (P ¼ .0002) and
IFD (P ¼ .0068), whereas the grade of aGVHD was signiﬁ-
cantly associated with the rate of IFD (P< .0001) but not with
Table 2
Univariate and Multivariable Analysis of Risk Factors Associated with the Development of Infectious Episodes
Risk Factor Infectious Episodes (n ¼ 134)
Univariate Analysis Multivariable Analysis
HR (95% CI) P Value HR (95% CI) P Value
Gender .0843 .1291
Male ref. ref.
Female .73 (.50-1.05) .76 (.53-1.08)
Underlying disease .4754 .2743
Nonmalignant ref. ref.
Malignant .88 (.63-1.22) .79 (.54-1.15)
Age at HSCT .99 (.97-1.03) .9206 1.01 (.98-1.04) .6616
Type of donor .0022 .0052
Matched related ref. ref.
Alternative 1.94 (1.19-3.18) 1.91 (1.19-3.05)
Source of stem cells .4973 .6809
Bone marrow ref. ref.
Cord blood 1.28 (.84-1.96) 1.04 (.64-1.68)
Peripheral blood .84 (.46-1.53) .77 (.40-1.47)
Type of conditioning regimen .3347 .4638
Nonmyeloablative ref ref.
Myeloablative 1.23 (.78-1.93) 1.21 (.73-1.99)
Grade of acute GVHD .6517 .9136
Absent/mild ref. ref.
Severe 1.02 (.69-1.50) 1.01 (.68-1.49)
Not evaluable 1.43 (.80-2.57) 1.18 (.65-2.12)
Refractory acute GVHD .3920 -
No ref. -
Yes 1.24 (.85-1.82)
GVHD indicates graft-versus-host disease; HR, (subdistribution) hazard ratio; HSCT, hemopoietic stem cell transplantation.
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multivariable analysis for the rate of bacteremia and IFD. The
rate of bacteremia was still signiﬁcantly associated with the
type of donor (P ¼ .0001), with an incidence rate ratio that
was more than 2 times higher in AD recipients compared
with those receiving HSCT from a MRD (Table 4, Panel A),
whereas that of IFD was signiﬁcantly associated only with
aGVHD grade (P < .0001) (Table 4, Panel B). In this case,
compared with those with absent/mild aGVHD, childrenTable 3
Multivariable Analysis of Risk Factors Associated with the Development of Bactere
Risk Factor Panel A: Bacteremia
HR (95% CI)
Gender
Male ref.
Female .74 (.51-1.10)
Underlying disease
Nonmalignant ref.
Malignant .67 (.45-.99)
Age at HSCT 1.01 (.98-1.05)
Type of donor
Matched related ref.
Alternative 1.85 (1.15-2.98)
Source of stem cells
Bone marrow ref.
Cord blood 1.32 (.80-2.18)
Peripheral blood .48 (.21-1.10)
Type of conditioning regimen
Nonmyeloablative ref.
Myeloablative 1.23 (.75-2.04)
Grade of acute GVHD
Absent/mild ref.
Severe .66 (.40-1.09)
Not evaluable .32 (.09-1.17)
Refractory acute GVHD
No -
Yes
GVHD indicates graft-versus-host disease; HR, (subdistribution) hazard ratio; HSCexperiencing severe aGVHD had almost 4 times increased
risk of IFD, whereas those without engraftment had > 24
times increased risk of IFD.
DISCUSSION
Severe infections represent an important complication
after allogeneic HSCT. Studies, mostly on allogeneic HSCT in
adults, have shown that aGVHD, steroids administration, and
secondary neutropenia are associated with the developmentmia and Invasive Fungal Disease
Panel B: Invasive Fungal Disease
P Value HR (95% CI) P Value
.1615 .5940
ref.
.81 (.43-1.55)
.1011 .4012
ref
1.51 (.71-3.21)
.5211 .99 (.94-1.05) .8702
.0171 .1445
ref
2.13 (.84-5.38)
.1132 .0987
ref
.23 (.03-1.86)
1.86 (.68-5.07)
.4873 .9419
ref.
1.04 (.42-2.55)
.0660 .0002
ref.
3.21 (1.62-6.36)
8.71 (4.22-17.99)
-
T, hemopoietic stem cell transplantation.
Table 4
Multivariable Analysis of Incidence Rates of Bacteremia or Invasive Fungal Disease in Children Undergoing Allogeneic HSCT
Risk Factor Panel A: Bacteremias Panel B: Invasive Fungal Disease
n/pdr IR (95% CI) IRR (95% CI) P n/pdr IR (95% CI) IRR (95% CI) P
Type of donor .0001 .0746
Matched related 18/35,580 .50 (.31-.86) ref. 4/35,580 .11 (.04-.38) ref
Alternative 85/68,537 1.24 (.97-1.60) 2.49 (1.42-4.39) 27/68,537 .39 (.26-.60) 2.43 (.85-6.95)
Grade of acute GVHD .5536 < .0001
Absent/mild 85/83,959 1.01 (.79-1.31) ref. 13/83,959 .15 (.09-.30) ref.
Severe 16/18,864 .85 (.48-1.54) .76 (.39-1.46) 12/18,864 .64 (.34-1.22) 3.74 (1.56-8.97)
Not evaluable 2/1294 1.55 (.36-12.25) 1.22 (.32-4.69) 6/1294 4.64 (1.91-12.01) 24.01 (8.26-69.83)
GVHD indicates graft-versus-host disease; IR, incidence rate (episodes/1000 pdr); IRR, incidence rate ratio; pdr, patient-days at risk; HSCT, hematopoietic stem
cell transplantation; CI, conﬁdence interval.
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ﬁrst study that analyzed the role aGVHD, together with other
risk factors, on the development of severe infections
(bacteremia and IFD) in a pediatric setting. This study con-
ﬁrms that the type of donor (AD versus MRD) is still the most
important risk factor for the development of a severe infec-
tion in pediatric allogeneic HSCT, as previously described [1].
However, the aim of our study was also to determine if
different factors were associated with risk of speciﬁc infec-
tious complications, namely bacteremia or IFD. Regarding
bacteremias, the type of donor was found to be associated to
the risk of this complication, as also shown by Frere et al. in a
selected cohort of adults [16], receiving MA HSCT. However,
in our study, we did not ﬁnd any speciﬁc role of the type of
conditioning regimen. We also observed a lower but not
signiﬁcant HR of bacteremias, in particular, in children with
aGVHD not evaluable (ie, engraftment failure or early death).
This observation is probably due to the fact that 82.5% of the
observed bacteremias occurred in the group of HSCT
complicated by grade 0 to I aGVHD that represents only
44.7% of all the study population. Clearly, the proportion of
bacteremias in other aGVHD groups was lower, and this
could explain the apparent protection from bacteremia in the
presence of severe aGVHD, and even in cases when GVHD is
not evaluable. The absence of a clinical relevance of this
observation is sustained by the wide 95% CI of the hazards
that include the value “1” [17], and it is further conﬁrmed by
the high rate of bacteremias, just observed in absence of
engraftment failure, that is expected in presence of pro-
longed neutropenia after HSCT [18,19].
Results were different regarding the risk of IFD. In fact, in
this case, we conﬁrmed that aGVHD, especially of severe
grade, has a pivotal role in the development of IFD, as already
reported both in children and adults [15,20-22], as it was the
only factor statistically associated with the risk of this
complication in the multivariable models also. In fact, in case
of severe aGVHD, the HR of IFDwasmore than 3 times higher
than for thosewithmild or absent aGVHD. Moreover, the risk
of IFD was more than 8 times higher in absence of engraft-
ment or early death. Engraftment failure has been described
as an important risk factor for the development of IFD
[23,24], and the present data quantify this risk, at least in the
pediatric population.
This study conﬁrms that both bacteremias and IFD may
occur very late during the follow-up of patients receiving
allogeneic HSCT [1,25], and it shows that these complications
occur later in presence of severe aGVHD. Moreover, in our
previous study showing the relationship between incidence
of infectious complications and type of HSCT donor [1], weobserved that bacteremias were 3 to 6 times more frequent
than IFD, and this observation was conﬁrmed by the present
results.
In conclusion, our data show that type of HSCT donor is
pivotal for the development of severe infectious complica-
tions after pediatric allogeneic HSCT. In these settings, severe
aGVHD plays an important role in the development of IFD,
although it does not represent a signiﬁcant risk factor for
bacteremia. These results must be kept in mind for the
development of management strategies.
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